Viridian Therapeutics, Inc.
VRDN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $70,570 | $75 | $72 | $72 |
| % Growth | 93,993.3% | 4.2% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $70,570 | $75 | $72 | $72 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $86,261 | $86,626 | $76,835 | $71,960 |
| G&A Expenses | $24,322 | $20,216 | $17,103 | $15,584 |
| SG&A Expenses | $24,322 | $20,216 | $17,103 | $15,584 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $110,583 | $106,842 | $93,938 | $87,544 |
| Operating Income | -$40,013 | -$106,767 | -$93,866 | -$87,472 |
| % Margin | -56.7% | -142,356% | -130,369.4% | -121,488.9% |
| Other Income/Exp. Net | $5,414 | $6,032 | $6,954 | $7,747 |
| Pre-Tax Income | -$34,599 | -$100,735 | -$86,912 | -$79,725 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$34,599 | -$100,735 | -$86,912 | -$79,725 |
| % Margin | -49% | -134,313.3% | -120,711.1% | -110,729.2% |
| EPS | -0.34 | -1 | -0.87 | -0.81 |
| % Growth | 66% | -14.9% | -7.4% | – |
| EPS Diluted | -0.34 | -1 | -0.87 | -0.81 |
| Weighted Avg Shares Out | 81,784 | 81,593 | 81,344 | 80,052 |
| Weighted Avg Shares Out Dil | 81,784 | 81,593 | 81,344 | 80,052 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,521 | $6,546 | $7,540 | $8,605 |
| Interest Expense | $560 | $514 | $586 | $858 |
| Depreciation & Amortization | $110 | $113 | $117 | $123 |
| EBITDA | -$33,929 | -$100,108 | -$86,209 | -$78,744 |
| % Margin | -48.1% | -133,477.3% | -119,734.7% | -109,366.7% |